Entera Bio Ltd. — Form 8-K
Filed July 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Entera Bio Ltd. entered into a securities purchase agreement dated July 26, 2026, to issue ordinary shares and pre-funded warrants at $2.04 per share to multiple purchasers, with a minimum aggregate subscription of $210 million required for closing. BVF Partners L.P. and its affiliates are designated purchasers with board designation and voting rights. The company reserved shares, granted registration rights, and agreed to board seat appointments conditional on BVF maintaining 75% or more ownership of purchased shares.
Why this rating
At $84.6M market cap, $210M minimum capital infusion is transformational (2.5x+ company size). Dilutive but strengthens balance sheet materially. Board control by BVF is meaningful governance change.
See more from July 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.